Last reviewed · How we verify

Cryotherapy + Tirbanibulin — Competitive Intelligence Brief

Cryotherapy + Tirbanibulin (Cryotherapy + Tirbanibulin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: cryotherapy + Src kinase inhibitor. Area: Dermatology/Oncology.

phase 3 Combination therapy: cryotherapy + Src kinase inhibitor Src kinase (tirbanibulin component) Dermatology/Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Cryotherapy + Tirbanibulin (Cryotherapy + Tirbanibulin) — University Hospital, Lille. Cryotherapy physically destroys actinic keratosis lesions through freezing, while tirbanibulin is a non-steroidal topical agent that induces keratinocyte apoptosis to treat actinic keratosis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cryotherapy + Tirbanibulin TARGET Cryotherapy + Tirbanibulin University Hospital, Lille phase 3 Combination therapy: cryotherapy + Src kinase inhibitor Src kinase (tirbanibulin component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: cryotherapy + Src kinase inhibitor class)

  1. University Hospital, Lille · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cryotherapy + Tirbanibulin — Competitive Intelligence Brief. https://druglandscape.com/ci/cryotherapy-tirbanibulin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: